Evidence map›Paper›PMID 37476702›Full record

ArticleJournal of rheumatic diseases2022

Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea.

Su Jin Choi, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Su Jin ChoiDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Soo Min AhnDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ji Seon OhDepartment of Information Medicine, Asan Medical Center, Seoul, Korea.
Seokchan HongDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Chang-Keun LeeDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Bin YooDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yong-Gil KimDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID 0000-0002-8029-7355
Ulsan College · KRAsan Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Previous studies investigating the beneficial effect of rituximab on lupus nephritis (LN) reported controversial results There have been few reports of renal response to rituximab according to renal function We investigated the efficacy of rituximab in refractory/relapsing LN and the role of renal function as a predictor of renal response. Methods: From 2016 to 2019, we retrospectively reviewed 22 patients with refractory/relapsing LN receiving rituximab Renal responses (complete and partial) at 6 and 12 months were compared between normal (glomerular filtration rate [GFR]≥90 mL/min/173 m Results: At baseline, the decreased GFR group had a higher urine proteinuria to creatinine ratio (p=0008) and proportion of refractory LN (p=0010) and previous cyclophosphamide therapy (p=0035) than the normal GFR group The overall renal response rate was 455% (10 patients) at 6 months and 545% (12 patients) at 12 months Renal response rates were higher in the normal GFR group (818% and 909% at 6 and 12 months, respectively) than in the decreased GFR group (91% and 182% at 6 and 12 months, respectively; p<0001) Normal GFR and anti-La were associated with renal response to rituximab, with hazard ratios of 9256 (p=0008) and 5478 (p=0041), respectively. Conclusion: Rituximab is an effective therapy for refractory/relapsing LN, particularly in patients with preserved renal function.

Indexed as

Glomerular filtration rateKidneyLupus nephritisRituximabSystemic lupus erythematosus

Identifiers

PMID37476702
PMCPMC10324915
OpenAlexW4200086084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.